nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP1A2—type 2 diabetes mellitus	0.137	0.602	CbGaD
Buprenorphine—CYP3A4—type 2 diabetes mellitus	0.0907	0.398	CbGaD
Buprenorphine—CYP2C18—Tolbutamide—type 2 diabetes mellitus	0.0438	0.0836	CbGbCtD
Buprenorphine—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.0372	0.0711	CbGbCtD
Buprenorphine—CYP2A6—Rosiglitazone—type 2 diabetes mellitus	0.022	0.0421	CbGbCtD
Buprenorphine—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0163	0.0311	CbGbCtD
Buprenorphine—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.013	0.0249	CbGbCtD
Buprenorphine—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.0124	0.0236	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.0124	0.0236	CbGbCtD
Buprenorphine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0124	0.0236	CbGbCtD
Buprenorphine—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0118	0.0225	CbGbCtD
Buprenorphine—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0116	0.0222	CbGbCtD
Buprenorphine—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0114	0.0217	CbGbCtD
Buprenorphine—ABCG2—Glyburide—type 2 diabetes mellitus	0.0113	0.0216	CbGbCtD
Buprenorphine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.011	0.0211	CbGbCtD
Buprenorphine—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0109	0.0208	CbGbCtD
Buprenorphine—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0105	0.02	CbGbCtD
Buprenorphine—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0104	0.0198	CbGbCtD
Buprenorphine—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.00987	0.0189	CbGbCtD
Buprenorphine—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.00987	0.0189	CbGbCtD
Buprenorphine—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00966	0.0184	CbGbCtD
Buprenorphine—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.00928	0.0177	CbGbCtD
Buprenorphine—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.00911	0.0174	CbGbCtD
Buprenorphine—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0088	0.0168	CbGbCtD
Buprenorphine—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00855	0.0163	CbGbCtD
Buprenorphine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00841	0.0161	CbGbCtD
Buprenorphine—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00821	0.0157	CbGbCtD
Buprenorphine—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00821	0.0157	CbGbCtD
Buprenorphine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00797	0.0152	CbGbCtD
Buprenorphine—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00758	0.0145	CbGbCtD
Buprenorphine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00751	0.0143	CbGbCtD
Buprenorphine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00741	0.0142	CbGbCtD
Buprenorphine—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00732	0.014	CbGbCtD
Buprenorphine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00693	0.0132	CbGbCtD
Buprenorphine—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00669	0.0128	CbGbCtD
Buprenorphine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00662	0.0126	CbGbCtD
Buprenorphine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0066	0.0126	CbGbCtD
Buprenorphine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00626	0.012	CbGbCtD
Buprenorphine—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00622	0.0119	CbGbCtD
Buprenorphine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00604	0.0115	CbGbCtD
Buprenorphine—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00596	0.0114	CbGbCtD
Buprenorphine—CYP3A5—Losartan—type 2 diabetes mellitus	0.00573	0.0109	CbGbCtD
Buprenorphine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00569	0.0109	CbGbCtD
Buprenorphine—CYP2C8—Losartan—type 2 diabetes mellitus	0.00551	0.0105	CbGbCtD
Buprenorphine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00547	0.0105	CbGbCtD
Buprenorphine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00545	0.0104	CbGbCtD
Buprenorphine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00528	0.0101	CbGbCtD
Buprenorphine—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00505	0.00966	CbGbCtD
Buprenorphine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00477	0.00912	CbGbCtD
Buprenorphine—CYP2C19—Losartan—type 2 diabetes mellitus	0.00462	0.00883	CbGbCtD
Buprenorphine—CYP1A2—Losartan—type 2 diabetes mellitus	0.00427	0.00815	CbGbCtD
Buprenorphine—CYP2C9—Glyburide—type 2 diabetes mellitus	0.0042	0.00803	CbGbCtD
Buprenorphine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00408	0.00779	CbGbCtD
Buprenorphine—CYP2C9—Losartan—type 2 diabetes mellitus	0.00384	0.00734	CbGbCtD
Buprenorphine—ABCB1—Losartan—type 2 diabetes mellitus	0.00373	0.00713	CbGbCtD
Buprenorphine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00362	0.00691	CbGbCtD
Buprenorphine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00347	0.00663	CbGbCtD
Buprenorphine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00347	0.00663	CbGbCtD
Buprenorphine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00328	0.00627	CbGbCtD
Buprenorphine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00244	0.00467	CbGbCtD
Buprenorphine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00224	0.00427	CbGbCtD
Buprenorphine—OPRM1—nerve—type 2 diabetes mellitus	0.000258	0.109	CbGeAlD
Buprenorphine—UGT1A9—kidney—type 2 diabetes mellitus	0.000164	0.0695	CbGeAlD
Buprenorphine—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000132	0.0559	CbGeAlD
Buprenorphine—OPRD1—kidney—type 2 diabetes mellitus	0.000129	0.0549	CbGeAlD
Buprenorphine—Oxymorphone—CYP3A4—type 2 diabetes mellitus	0.00012	0.423	CrCbGaD
Buprenorphine—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000113	0.0479	CbGeAlD
Buprenorphine—UGT1A9—liver—type 2 diabetes mellitus	0.000104	0.0439	CbGeAlD
Buprenorphine—CYP2C18—liver—type 2 diabetes mellitus	9.05e-05	0.0384	CbGeAlD
Buprenorphine—Naloxone—CYP3A4—type 2 diabetes mellitus	8.79e-05	0.308	CrCbGaD
Buprenorphine—CYP3A7—liver—type 2 diabetes mellitus	8.61e-05	0.0365	CbGeAlD
Buprenorphine—CYP2A6—adipose tissue—type 2 diabetes mellitus	8.53e-05	0.0362	CbGeAlD
Buprenorphine—Naloxone—ALB—type 2 diabetes mellitus	7.66e-05	0.269	CrCbGaD
Buprenorphine—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	7.32e-05	0.0311	CbGeAlD
Buprenorphine—Chest pain—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.000448	CcSEcCtD
Buprenorphine—Shock—Metformin—type 2 diabetes mellitus	7.07e-05	0.000448	CcSEcCtD
Buprenorphine—Insomnia—Orlistat—type 2 diabetes mellitus	7.05e-05	0.000447	CcSEcCtD
Buprenorphine—Malaise—Losartan—type 2 diabetes mellitus	7.05e-05	0.000447	CcSEcCtD
Buprenorphine—Anxiety—Irbesartan—type 2 diabetes mellitus	7.05e-05	0.000447	CcSEcCtD
Buprenorphine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	7.05e-05	0.000447	CcSEcCtD
Buprenorphine—Nervous system disorder—Metformin—type 2 diabetes mellitus	7.05e-05	0.000447	CcSEcCtD
Buprenorphine—Dyspnoea—Valsartan—type 2 diabetes mellitus	7.03e-05	0.000446	CcSEcCtD
Buprenorphine—Vertigo—Losartan—type 2 diabetes mellitus	7.03e-05	0.000445	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	7.03e-05	0.000445	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	7.02e-05	0.000445	CcSEcCtD
Buprenorphine—Somnolence—Valsartan—type 2 diabetes mellitus	7.01e-05	0.000445	CcSEcCtD
Buprenorphine—Syncope—Losartan—type 2 diabetes mellitus	7.01e-05	0.000444	CcSEcCtD
Buprenorphine—Paraesthesia—Orlistat—type 2 diabetes mellitus	7e-05	0.000444	CcSEcCtD
Buprenorphine—Discomfort—Irbesartan—type 2 diabetes mellitus	6.99e-05	0.000443	CcSEcCtD
Buprenorphine—Skin disorder—Metformin—type 2 diabetes mellitus	6.98e-05	0.000442	CcSEcCtD
Buprenorphine—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.96e-05	0.000441	CcSEcCtD
Buprenorphine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.95e-05	0.00044	CcSEcCtD
Buprenorphine—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.95e-05	0.00044	CcSEcCtD
Buprenorphine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.94e-05	0.00044	CcSEcCtD
Buprenorphine—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.000438	CcSEcCtD
Buprenorphine—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.000438	CcSEcCtD
Buprenorphine—Palpitations—Losartan—type 2 diabetes mellitus	6.91e-05	0.000438	CcSEcCtD
Buprenorphine—Nausea—Glimepiride—type 2 diabetes mellitus	6.89e-05	0.000437	CcSEcCtD
Buprenorphine—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.87e-05	0.000435	CcSEcCtD
Buprenorphine—Nausea—Sitagliptin—type 2 diabetes mellitus	6.87e-05	0.000435	CcSEcCtD
Buprenorphine—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.86e-05	0.000435	CcSEcCtD
Buprenorphine—Asthenia—Glyburide—type 2 diabetes mellitus	6.86e-05	0.000435	CcSEcCtD
Buprenorphine—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.86e-05	0.000435	CcSEcCtD
Buprenorphine—Anorexia—Metformin—type 2 diabetes mellitus	6.85e-05	0.000434	CcSEcCtD
Buprenorphine—Cough—Losartan—type 2 diabetes mellitus	6.82e-05	0.000432	CcSEcCtD
Buprenorphine—Urticaria—Gliclazide—type 2 diabetes mellitus	6.82e-05	0.000432	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.81e-05	0.000432	CcSEcCtD
Buprenorphine—Fatigue—Valsartan—type 2 diabetes mellitus	6.8e-05	0.000431	CcSEcCtD
Buprenorphine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.79e-05	0.00043	CcSEcCtD
Buprenorphine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.79e-05	0.00043	CcSEcCtD
Buprenorphine—Oedema—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.00043	CcSEcCtD
Buprenorphine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.00043	CcSEcCtD
Buprenorphine—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.78e-05	0.000429	CcSEcCtD
Buprenorphine—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	6.77e-05	0.0287	CbGeAlD
Buprenorphine—Pruritus—Glyburide—type 2 diabetes mellitus	6.77e-05	0.000429	CcSEcCtD
Buprenorphine—Mental disorder—Ramipril—type 2 diabetes mellitus	6.75e-05	0.000428	CcSEcCtD
Buprenorphine—Constipation—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000428	CcSEcCtD
Buprenorphine—Infection—Irbesartan—type 2 diabetes mellitus	6.74e-05	0.000427	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.73e-05	0.000427	CcSEcCtD
Buprenorphine—Fatigue—Orlistat—type 2 diabetes mellitus	6.72e-05	0.000426	CcSEcCtD
Buprenorphine—Hypotension—Metformin—type 2 diabetes mellitus	6.71e-05	0.000425	CcSEcCtD
Buprenorphine—Malnutrition—Ramipril—type 2 diabetes mellitus	6.7e-05	0.000425	CcSEcCtD
Buprenorphine—Erythema—Ramipril—type 2 diabetes mellitus	6.7e-05	0.000425	CcSEcCtD
Buprenorphine—Shock—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.000423	CcSEcCtD
Buprenorphine—Pain—Orlistat—type 2 diabetes mellitus	6.67e-05	0.000422	CcSEcCtD
Buprenorphine—Myalgia—Losartan—type 2 diabetes mellitus	6.66e-05	0.000422	CcSEcCtD
Buprenorphine—Arthralgia—Losartan—type 2 diabetes mellitus	6.66e-05	0.000422	CcSEcCtD
Buprenorphine—Chest pain—Losartan—type 2 diabetes mellitus	6.66e-05	0.000422	CcSEcCtD
Buprenorphine—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.65e-05	0.000422	CcSEcCtD
Buprenorphine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.65e-05	0.000421	CcSEcCtD
Buprenorphine—Anxiety—Losartan—type 2 diabetes mellitus	6.63e-05	0.00042	CcSEcCtD
Buprenorphine—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.62e-05	0.000419	CcSEcCtD
Buprenorphine—Rash—Bromocriptine—type 2 diabetes mellitus	6.6e-05	0.000418	CcSEcCtD
Buprenorphine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.59e-05	0.000418	CcSEcCtD
Buprenorphine—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.59e-05	0.000417	CcSEcCtD
Buprenorphine—Tension—Ramipril—type 2 diabetes mellitus	6.58e-05	0.000417	CcSEcCtD
Buprenorphine—Discomfort—Losartan—type 2 diabetes mellitus	6.58e-05	0.000417	CcSEcCtD
Buprenorphine—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.57e-05	0.000416	CcSEcCtD
Buprenorphine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.56e-05	0.000415	CcSEcCtD
Buprenorphine—Headache—Bromocriptine—type 2 diabetes mellitus	6.55e-05	0.000415	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.55e-05	0.000415	CcSEcCtD
Buprenorphine—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.54e-05	0.000415	CcSEcCtD
Buprenorphine—Nervousness—Ramipril—type 2 diabetes mellitus	6.51e-05	0.000413	CcSEcCtD
Buprenorphine—Dry mouth—Losartan—type 2 diabetes mellitus	6.51e-05	0.000413	CcSEcCtD
Buprenorphine—Anorexia—Irbesartan—type 2 diabetes mellitus	6.46e-05	0.00041	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.45e-05	0.000409	CcSEcCtD
Buprenorphine—Paraesthesia—Metformin—type 2 diabetes mellitus	6.45e-05	0.000409	CcSEcCtD
Buprenorphine—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.45e-05	0.000408	CcSEcCtD
Buprenorphine—Confusional state—Losartan—type 2 diabetes mellitus	6.43e-05	0.000408	CcSEcCtD
Buprenorphine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.43e-05	0.000407	CcSEcCtD
Buprenorphine—Dyspnoea—Metformin—type 2 diabetes mellitus	6.41e-05	0.000406	CcSEcCtD
Buprenorphine—Somnolence—Metformin—type 2 diabetes mellitus	6.39e-05	0.000405	CcSEcCtD
Buprenorphine—Oedema—Losartan—type 2 diabetes mellitus	6.38e-05	0.000404	CcSEcCtD
Buprenorphine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	6.38e-05	0.000404	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.38e-05	0.000404	CcSEcCtD
Buprenorphine—Infection—Losartan—type 2 diabetes mellitus	6.34e-05	0.000402	CcSEcCtD
Buprenorphine—Hypotension—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000402	CcSEcCtD
Buprenorphine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.33e-05	0.000401	CcSEcCtD
Buprenorphine—Dyspepsia—Metformin—type 2 diabetes mellitus	6.33e-05	0.000401	CcSEcCtD
Buprenorphine—Tremor—Ramipril—type 2 diabetes mellitus	6.28e-05	0.000398	CcSEcCtD
Buprenorphine—Shock—Losartan—type 2 diabetes mellitus	6.28e-05	0.000398	CcSEcCtD
Buprenorphine—Urticaria—Valsartan—type 2 diabetes mellitus	6.27e-05	0.000397	CcSEcCtD
Buprenorphine—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.26e-05	0.000397	CcSEcCtD
Buprenorphine—Decreased appetite—Metformin—type 2 diabetes mellitus	6.25e-05	0.000396	CcSEcCtD
Buprenorphine—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.24e-05	0.000395	CcSEcCtD
Buprenorphine—Tachycardia—Losartan—type 2 diabetes mellitus	6.23e-05	0.000395	CcSEcCtD
Buprenorphine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	6.22e-05	0.000394	CcSEcCtD
Buprenorphine—Nausea—Bromocriptine—type 2 diabetes mellitus	6.21e-05	0.000394	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.2e-05	0.000393	CcSEcCtD
Buprenorphine—Fatigue—Metformin—type 2 diabetes mellitus	6.2e-05	0.000393	CcSEcCtD
Buprenorphine—Urticaria—Orlistat—type 2 diabetes mellitus	6.19e-05	0.000392	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.18e-05	0.000391	CcSEcCtD
Buprenorphine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.17e-05	0.000391	CcSEcCtD
Buprenorphine—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.16e-05	0.000391	CcSEcCtD
Buprenorphine—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.16e-05	0.000391	CcSEcCtD
Buprenorphine—Asthenia—Gliclazide—type 2 diabetes mellitus	6.16e-05	0.00039	CcSEcCtD
Buprenorphine—Agitation—Ramipril—type 2 diabetes mellitus	6.16e-05	0.00039	CcSEcCtD
Buprenorphine—Constipation—Metformin—type 2 diabetes mellitus	6.14e-05	0.000389	CcSEcCtD
Buprenorphine—Angioedema—Ramipril—type 2 diabetes mellitus	6.13e-05	0.000388	CcSEcCtD
Buprenorphine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.000386	CcSEcCtD
Buprenorphine—Anorexia—Losartan—type 2 diabetes mellitus	6.08e-05	0.000385	CcSEcCtD
Buprenorphine—Vomiting—Glyburide—type 2 diabetes mellitus	6.08e-05	0.000385	CcSEcCtD
Buprenorphine—Pruritus—Gliclazide—type 2 diabetes mellitus	6.08e-05	0.000385	CcSEcCtD
Buprenorphine—Malaise—Ramipril—type 2 diabetes mellitus	6.05e-05	0.000383	CcSEcCtD
Buprenorphine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.05e-05	0.000383	CcSEcCtD
Buprenorphine—Rash—Glyburide—type 2 diabetes mellitus	6.03e-05	0.000382	CcSEcCtD
Buprenorphine—Somnolence—Irbesartan—type 2 diabetes mellitus	6.03e-05	0.000382	CcSEcCtD
Buprenorphine—Dermatitis—Glyburide—type 2 diabetes mellitus	6.03e-05	0.000382	CcSEcCtD
Buprenorphine—Vertigo—Ramipril—type 2 diabetes mellitus	6.02e-05	0.000382	CcSEcCtD
Buprenorphine—Syncope—Ramipril—type 2 diabetes mellitus	6.01e-05	0.000381	CcSEcCtD
Buprenorphine—Headache—Glyburide—type 2 diabetes mellitus	5.99e-05	0.00038	CcSEcCtD
Buprenorphine—CYP2A6—liver—type 2 diabetes mellitus	5.98e-05	0.0254	CbGeAlD
Buprenorphine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.97e-05	0.000378	CcSEcCtD
Buprenorphine—Hypotension—Losartan—type 2 diabetes mellitus	5.96e-05	0.000378	CcSEcCtD
Buprenorphine—Palpitations—Ramipril—type 2 diabetes mellitus	5.93e-05	0.000375	CcSEcCtD
Buprenorphine—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.92e-05	0.000375	CcSEcCtD
Buprenorphine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.89e-05	0.000374	CcSEcCtD
Buprenorphine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.89e-05	0.000373	CcSEcCtD
Buprenorphine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.88e-05	0.000372	CcSEcCtD
Buprenorphine—ABCG2—nephron tubule—type 2 diabetes mellitus	5.88e-05	0.0249	CbGeAlD
Buprenorphine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.88e-05	0.000372	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.85e-05	0.000371	CcSEcCtD
Buprenorphine—Cough—Ramipril—type 2 diabetes mellitus	5.85e-05	0.000371	CcSEcCtD
Buprenorphine—Fatigue—Irbesartan—type 2 diabetes mellitus	5.85e-05	0.00037	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.81e-05	0.000368	CcSEcCtD
Buprenorphine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.81e-05	0.000368	CcSEcCtD
Buprenorphine—Convulsion—Ramipril—type 2 diabetes mellitus	5.81e-05	0.000368	CcSEcCtD
Buprenorphine—Constipation—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000367	CcSEcCtD
Buprenorphine—Pain—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000367	CcSEcCtD
Buprenorphine—Insomnia—Losartan—type 2 diabetes mellitus	5.77e-05	0.000366	CcSEcCtD
Buprenorphine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.74e-05	0.000364	CcSEcCtD
Buprenorphine—Paraesthesia—Losartan—type 2 diabetes mellitus	5.73e-05	0.000363	CcSEcCtD
Buprenorphine—Urticaria—Metformin—type 2 diabetes mellitus	5.71e-05	0.000362	CcSEcCtD
Buprenorphine—Chest pain—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000362	CcSEcCtD
Buprenorphine—Myalgia—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000362	CcSEcCtD
Buprenorphine—Arthralgia—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000362	CcSEcCtD
Buprenorphine—Dyspnoea—Losartan—type 2 diabetes mellitus	5.69e-05	0.000361	CcSEcCtD
Buprenorphine—Anxiety—Ramipril—type 2 diabetes mellitus	5.69e-05	0.00036	CcSEcCtD
Buprenorphine—Nausea—Glyburide—type 2 diabetes mellitus	5.68e-05	0.00036	CcSEcCtD
Buprenorphine—Abdominal pain—Metformin—type 2 diabetes mellitus	5.68e-05	0.00036	CcSEcCtD
Buprenorphine—Dizziness—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.00036	CcSEcCtD
Buprenorphine—Somnolence—Losartan—type 2 diabetes mellitus	5.67e-05	0.000359	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000359	CcSEcCtD
Buprenorphine—Asthenia—Valsartan—type 2 diabetes mellitus	5.66e-05	0.000359	CcSEcCtD
Buprenorphine—Discomfort—Ramipril—type 2 diabetes mellitus	5.64e-05	0.000357	CcSEcCtD
Buprenorphine—Dyspepsia—Losartan—type 2 diabetes mellitus	5.62e-05	0.000356	CcSEcCtD
Buprenorphine—Asthenia—Orlistat—type 2 diabetes mellitus	5.59e-05	0.000354	CcSEcCtD
Buprenorphine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.59e-05	0.000354	CcSEcCtD
Buprenorphine—Pruritus—Valsartan—type 2 diabetes mellitus	5.58e-05	0.000354	CcSEcCtD
Buprenorphine—Dry mouth—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000354	CcSEcCtD
Buprenorphine—Decreased appetite—Losartan—type 2 diabetes mellitus	5.55e-05	0.000352	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.55e-05	0.000351	CcSEcCtD
Buprenorphine—Confusional state—Ramipril—type 2 diabetes mellitus	5.52e-05	0.00035	CcSEcCtD
Buprenorphine—Pruritus—Orlistat—type 2 diabetes mellitus	5.52e-05	0.00035	CcSEcCtD
Buprenorphine—Fatigue—Losartan—type 2 diabetes mellitus	5.5e-05	0.000349	CcSEcCtD
Buprenorphine—Oedema—Ramipril—type 2 diabetes mellitus	5.47e-05	0.000347	CcSEcCtD
Buprenorphine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	5.47e-05	0.000347	CcSEcCtD
Buprenorphine—Vomiting—Gliclazide—type 2 diabetes mellitus	5.46e-05	0.000346	CcSEcCtD
Buprenorphine—Constipation—Losartan—type 2 diabetes mellitus	5.46e-05	0.000346	CcSEcCtD
Buprenorphine—Pain—Losartan—type 2 diabetes mellitus	5.46e-05	0.000346	CcSEcCtD
Buprenorphine—CYP3A5—nephron tubule—type 2 diabetes mellitus	5.45e-05	0.0231	CbGeAlD
Buprenorphine—Rash—Gliclazide—type 2 diabetes mellitus	5.42e-05	0.000343	CcSEcCtD
Buprenorphine—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.41e-05	0.000343	CcSEcCtD
Buprenorphine—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.4e-05	0.000342	CcSEcCtD
Buprenorphine—Urticaria—Irbesartan—type 2 diabetes mellitus	5.39e-05	0.000341	CcSEcCtD
Buprenorphine—Shock—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000341	CcSEcCtD
Buprenorphine—Headache—Gliclazide—type 2 diabetes mellitus	5.38e-05	0.000341	CcSEcCtD
Buprenorphine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.37e-05	0.00034	CcSEcCtD
Buprenorphine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.36e-05	0.00034	CcSEcCtD
Buprenorphine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.36e-05	0.00034	CcSEcCtD
Buprenorphine—Tachycardia—Ramipril—type 2 diabetes mellitus	5.34e-05	0.000338	CcSEcCtD
Buprenorphine—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.33e-05	0.000338	CcSEcCtD
Buprenorphine—Skin disorder—Ramipril—type 2 diabetes mellitus	5.32e-05	0.000337	CcSEcCtD
Buprenorphine—CYP2C8—kidney—type 2 diabetes mellitus	5.31e-05	0.0225	CbGeAlD
Buprenorphine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.29e-05	0.000335	CcSEcCtD
Buprenorphine—Feeling abnormal—Losartan—type 2 diabetes mellitus	5.26e-05	0.000333	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.22e-05	0.000331	CcSEcCtD
Buprenorphine—Dizziness—Valsartan—type 2 diabetes mellitus	5.22e-05	0.000331	CcSEcCtD
Buprenorphine—Anorexia—Ramipril—type 2 diabetes mellitus	5.22e-05	0.000331	CcSEcCtD
Buprenorphine—Dizziness—Orlistat—type 2 diabetes mellitus	5.16e-05	0.000327	CcSEcCtD
Buprenorphine—Asthenia—Metformin—type 2 diabetes mellitus	5.16e-05	0.000327	CcSEcCtD
Buprenorphine—Hypotension—Ramipril—type 2 diabetes mellitus	5.11e-05	0.000324	CcSEcCtD
Buprenorphine—Nausea—Gliclazide—type 2 diabetes mellitus	5.1e-05	0.000323	CcSEcCtD
Buprenorphine—Pruritus—Metformin—type 2 diabetes mellitus	5.08e-05	0.000322	CcSEcCtD
Buprenorphine—Urticaria—Losartan—type 2 diabetes mellitus	5.07e-05	0.000321	CcSEcCtD
Buprenorphine—Abdominal pain—Losartan—type 2 diabetes mellitus	5.04e-05	0.00032	CcSEcCtD
Buprenorphine—Body temperature increased—Losartan—type 2 diabetes mellitus	5.04e-05	0.00032	CcSEcCtD
Buprenorphine—Vomiting—Valsartan—type 2 diabetes mellitus	5.02e-05	0.000318	CcSEcCtD
Buprenorphine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5e-05	0.000317	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000316	CcSEcCtD
Buprenorphine—Rash—Valsartan—type 2 diabetes mellitus	4.98e-05	0.000315	CcSEcCtD
Buprenorphine—Dermatitis—Valsartan—type 2 diabetes mellitus	4.97e-05	0.000315	CcSEcCtD
Buprenorphine—Vomiting—Orlistat—type 2 diabetes mellitus	4.96e-05	0.000314	CcSEcCtD
Buprenorphine—Insomnia—Ramipril—type 2 diabetes mellitus	4.95e-05	0.000314	CcSEcCtD
Buprenorphine—Headache—Valsartan—type 2 diabetes mellitus	4.94e-05	0.000313	CcSEcCtD
Buprenorphine—Diarrhoea—Metformin—type 2 diabetes mellitus	4.92e-05	0.000312	CcSEcCtD
Buprenorphine—Rash—Orlistat—type 2 diabetes mellitus	4.92e-05	0.000312	CcSEcCtD
Buprenorphine—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000311	CcSEcCtD
Buprenorphine—Dermatitis—Orlistat—type 2 diabetes mellitus	4.91e-05	0.000311	CcSEcCtD
Buprenorphine—Headache—Orlistat—type 2 diabetes mellitus	4.88e-05	0.00031	CcSEcCtD
Buprenorphine—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.88e-05	0.000309	CcSEcCtD
Buprenorphine—Asthenia—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000308	CcSEcCtD
Buprenorphine—Somnolence—Ramipril—type 2 diabetes mellitus	4.86e-05	0.000308	CcSEcCtD
Buprenorphine—CYP2C9—cardiovascular system—type 2 diabetes mellitus	4.82e-05	0.0205	CbGeAlD
Buprenorphine—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.82e-05	0.000305	CcSEcCtD
Buprenorphine—Pruritus—Irbesartan—type 2 diabetes mellitus	4.8e-05	0.000304	CcSEcCtD
Buprenorphine—CYP3A5—kidney—type 2 diabetes mellitus	4.79e-05	0.0203	CbGeAlD
Buprenorphine—CYP3A5—pancreas—type 2 diabetes mellitus	4.76e-05	0.0202	CbGeAlD
Buprenorphine—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000301	CcSEcCtD
Buprenorphine—Dizziness—Metformin—type 2 diabetes mellitus	4.75e-05	0.000301	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000299	CcSEcCtD
Buprenorphine—Fatigue—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000299	CcSEcCtD
Buprenorphine—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.7e-05	0.000298	CcSEcCtD
Buprenorphine—Nausea—Valsartan—type 2 diabetes mellitus	4.69e-05	0.000297	CcSEcCtD
Buprenorphine—Constipation—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000297	CcSEcCtD
Buprenorphine—CYP3A5—cortex of kidney—type 2 diabetes mellitus	4.67e-05	0.0198	CbGeAlD
Buprenorphine—ABCG2—adipose tissue—type 2 diabetes mellitus	4.65e-05	0.0197	CbGeAlD
Buprenorphine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.64e-05	0.000294	CcSEcCtD
Buprenorphine—Nausea—Orlistat—type 2 diabetes mellitus	4.63e-05	0.000293	CcSEcCtD
Buprenorphine—Asthenia—Losartan—type 2 diabetes mellitus	4.58e-05	0.00029	CcSEcCtD
Buprenorphine—Vomiting—Metformin—type 2 diabetes mellitus	4.57e-05	0.00029	CcSEcCtD
Buprenorphine—Rash—Metformin—type 2 diabetes mellitus	4.53e-05	0.000287	CcSEcCtD
Buprenorphine—Dermatitis—Metformin—type 2 diabetes mellitus	4.53e-05	0.000287	CcSEcCtD
Buprenorphine—Pruritus—Losartan—type 2 diabetes mellitus	4.52e-05	0.000286	CcSEcCtD
Buprenorphine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.51e-05	0.000286	CcSEcCtD
Buprenorphine—Headache—Metformin—type 2 diabetes mellitus	4.5e-05	0.000285	CcSEcCtD
Buprenorphine—Dizziness—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000284	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.47e-05	0.000284	CcSEcCtD
Buprenorphine—Diarrhoea—Losartan—type 2 diabetes mellitus	4.37e-05	0.000277	CcSEcCtD
Buprenorphine—Urticaria—Ramipril—type 2 diabetes mellitus	4.35e-05	0.000275	CcSEcCtD
Buprenorphine—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000274	CcSEcCtD
Buprenorphine—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000274	CcSEcCtD
Buprenorphine—CYP3A5—adipose tissue—type 2 diabetes mellitus	4.32e-05	0.0183	CbGeAlD
Buprenorphine—Vomiting—Irbesartan—type 2 diabetes mellitus	4.31e-05	0.000273	CcSEcCtD
Buprenorphine—Rash—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.000271	CcSEcCtD
Buprenorphine—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.27e-05	0.000271	CcSEcCtD
Buprenorphine—Nausea—Metformin—type 2 diabetes mellitus	4.27e-05	0.00027	CcSEcCtD
Buprenorphine—Headache—Irbesartan—type 2 diabetes mellitus	4.25e-05	0.000269	CcSEcCtD
Buprenorphine—Dizziness—Losartan—type 2 diabetes mellitus	4.22e-05	0.000267	CcSEcCtD
Buprenorphine—Vomiting—Losartan—type 2 diabetes mellitus	4.06e-05	0.000257	CcSEcCtD
Buprenorphine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000255	CcSEcCtD
Buprenorphine—Nausea—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000255	CcSEcCtD
Buprenorphine—Rash—Losartan—type 2 diabetes mellitus	4.02e-05	0.000255	CcSEcCtD
Buprenorphine—Dermatitis—Losartan—type 2 diabetes mellitus	4.02e-05	0.000255	CcSEcCtD
Buprenorphine—Headache—Losartan—type 2 diabetes mellitus	4e-05	0.000253	CcSEcCtD
Buprenorphine—Asthenia—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000249	CcSEcCtD
Buprenorphine—Pruritus—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000245	CcSEcCtD
Buprenorphine—CYP2C19—liver—type 2 diabetes mellitus	3.85e-05	0.0163	CbGeAlD
Buprenorphine—Nausea—Losartan—type 2 diabetes mellitus	3.79e-05	0.00024	CcSEcCtD
Buprenorphine—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000237	CcSEcCtD
Buprenorphine—Dizziness—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000229	CcSEcCtD
Buprenorphine—ABCB1—islet of Langerhans—type 2 diabetes mellitus	3.6e-05	0.0153	CbGeAlD
Buprenorphine—CYP3A4—kidney—type 2 diabetes mellitus	3.6e-05	0.0153	CbGeAlD
Buprenorphine—CYP2D6—kidney—type 2 diabetes mellitus	3.54e-05	0.015	CbGeAlD
Buprenorphine—Vomiting—Ramipril—type 2 diabetes mellitus	3.48e-05	0.00022	CcSEcCtD
Buprenorphine—Rash—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000219	CcSEcCtD
Buprenorphine—Dermatitis—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000218	CcSEcCtD
Buprenorphine—Headache—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000217	CcSEcCtD
Buprenorphine—CYP2C8—liver—type 2 diabetes mellitus	3.36e-05	0.0142	CbGeAlD
Buprenorphine—ABCG2—liver—type 2 diabetes mellitus	3.26e-05	0.0138	CbGeAlD
Buprenorphine—Nausea—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000206	CcSEcCtD
Buprenorphine—CYP1A2—liver—type 2 diabetes mellitus	3.14e-05	0.0133	CbGeAlD
Buprenorphine—ABCB1—retina—type 2 diabetes mellitus	3.08e-05	0.0131	CbGeAlD
Buprenorphine—CYP3A5—liver—type 2 diabetes mellitus	3.03e-05	0.0129	CbGeAlD
Buprenorphine—CYP2C9—liver—type 2 diabetes mellitus	2.98e-05	0.0127	CbGeAlD
Buprenorphine—ABCB1—nephron tubule—type 2 diabetes mellitus	2.9e-05	0.0123	CbGeAlD
Buprenorphine—ABCB1—cardiovascular system—type 2 diabetes mellitus	2.6e-05	0.011	CbGeAlD
Buprenorphine—ABCB1—kidney—type 2 diabetes mellitus	2.55e-05	0.0108	CbGeAlD
Buprenorphine—ABCB1—pancreas—type 2 diabetes mellitus	2.53e-05	0.0107	CbGeAlD
Buprenorphine—ABCB1—cortex of kidney—type 2 diabetes mellitus	2.48e-05	0.0105	CbGeAlD
Buprenorphine—ABCB1—adipose tissue—type 2 diabetes mellitus	2.3e-05	0.00974	CbGeAlD
Buprenorphine—CYP3A4—liver—type 2 diabetes mellitus	2.27e-05	0.00965	CbGeAlD
Buprenorphine—CYP2D6—liver—type 2 diabetes mellitus	2.24e-05	0.00949	CbGeAlD
Buprenorphine—ABCB1—liver—type 2 diabetes mellitus	1.61e-05	0.00683	CbGeAlD
Buprenorphine—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	2.66e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	2.66e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	2.66e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	2.64e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.63e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	2.62e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.62e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	2.6e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.6e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	2.6e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.6e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	2.6e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	2.59e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	2.59e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.59e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.59e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.59e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.59e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	2.58e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	2.58e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	2.57e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	2.56e-06	2.9e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—type 2 diabetes mellitus	2.55e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.54e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.54e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	2.54e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.53e-06	2.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	2.52e-06	2.86e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.52e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.5e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	2.49e-06	2.82e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	2.48e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	2.48e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.46e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	2.46e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	2.46e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.45e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3R1—type 2 diabetes mellitus	2.44e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NOS3—type 2 diabetes mellitus	2.44e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.44e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	2.44e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.43e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.42e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	2.42e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.4e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.4e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.4e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.4e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	2.39e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	2.39e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.38e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.38e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.38e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.37e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	2.37e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	2.37e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	2.36e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.36e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	2.35e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	2.35e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.35e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.35e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	2.35e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.34e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.34e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.34e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	2.33e-06	2.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.32e-06	2.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	2.32e-06	2.63e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.31e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	2.31e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.31e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.28e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.28e-06	2.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	2.27e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.27e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.27e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.27e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	2.26e-06	2.56e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.26e-06	2.56e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.25e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	2.25e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	2.24e-06	2.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	2.23e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—type 2 diabetes mellitus	2.23e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	2.23e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	2.22e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.22e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.22e-06	2.51e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.21e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	2.2e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	2.2e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.2e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.2e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	2.2e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.18e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.18e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.17e-06	2.46e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	2.16e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.13e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	2.13e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.13e-06	2.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	2.12e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	2.11e-06	2.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.1e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.1e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.1e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	2.09e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.08e-06	2.36e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.08e-06	2.35e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.07e-06	2.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.06e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.06e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	2.05e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.05e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.04e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.04e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.03e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	2.03e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	2.03e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	2.03e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.03e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	2.02e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.02e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	2.01e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.99e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.99e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.99e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.99e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.99e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.98e-06	2.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.96e-06	2.22e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.96e-06	2.22e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.95e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	1.95e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.94e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.94e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.93e-06	2.19e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.93e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.93e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.93e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.92e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.92e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.92e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	1.91e-06	2.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	1.9e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.9e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.9e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.88e-06	2.13e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.87e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.87e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	1.85e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.85e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—type 2 diabetes mellitus	1.84e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.83e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.83e-06	2.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	1.82e-06	2.06e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.82e-06	2.06e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.82e-06	2.06e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	1.81e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.81e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.81e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.8e-06	2.04e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	1.79e-06	2.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.76e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.76e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.74e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.74e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.73e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.73e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.71e-06	1.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	1.7e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.69e-06	1.91e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.68e-06	1.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.67e-06	1.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.67e-06	1.89e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.66e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.66e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.63e-06	1.85e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.61e-06	1.82e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.59e-06	1.8e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.58e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	1.58e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.57e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.57e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.56e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.56e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	1.56e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.55e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.55e-06	1.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	1.55e-06	1.75e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.54e-06	1.74e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.53e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.53e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	1.53e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.52e-06	1.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.49e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	1.49e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	1.49e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	1.46e-06	1.65e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.45e-06	1.65e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.45e-06	1.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.45e-06	1.64e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.43e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.43e-06	1.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	1.42e-06	1.61e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.41e-06	1.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.4e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.39e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.37e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.37e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	1.36e-06	1.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	1.36e-06	1.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	1.36e-06	1.54e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.35e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.35e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.34e-06	1.51e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.33e-06	1.51e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1.32e-06	1.5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.29e-06	1.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.28e-06	1.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.26e-06	1.43e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.25e-06	1.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	1.24e-06	1.41e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	1.24e-06	1.4e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	1.22e-06	1.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.22e-06	1.38e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	1.21e-06	1.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.2e-06	1.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.2e-06	1.35e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.19e-06	1.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.18e-06	1.34e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.16e-06	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.16e-06	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—type 2 diabetes mellitus	1.12e-06	1.27e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.06e-06	1.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.04e-06	1.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.02e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	9.36e-07	1.06e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	8.95e-07	1.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	8.95e-07	1.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	8.85e-07	1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	8.19e-07	9.27e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	7.67e-07	8.68e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	6.84e-07	7.75e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	6.68e-07	7.56e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	6.3e-07	7.13e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	6.24e-07	7.07e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	5.33e-07	6.04e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.12e-07	4.66e-06	CbGpPWpGaD
